Zobrazeno 1 - 8
of 8
pro vyhledávání: '"John M. Strother"'
Autor:
Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
Publikováno v:
Clinical Genitourinary Cancer. 20:415-422
Overexpression of the epidermal growth factor receptor (EGFR) and its ligands occur frequently in renal cell carcinoma (RCC). Combined vascular endothelial growth factor receptor (VEGF-R) and EGFR inhibition may overcome resistance to VEGF-R inhibito
Autor:
John M. Strother, Kerstin M Kampa-Schittenhelm, Matthew R. Kearney, Kendra Todd, Charles D. Lopez, Emerson Y. Chen, Jeff Donovan, Gina M. Vaccaro, Andrea Burt
Publikováno v:
Anticancer research. 39(1)
Background Based on our pre-clinical data, we hypothesized that sequencing chemotherapy with erlotinib would increase the tumor response rate in patients with metastatic colorectal cancer. Patients and methods A phase II trial (planned n=58) using se
Autor:
Michael J. Ratz, John M. Strother, Chelsea Dice, Baiyang Xu, Erich Lieth, Diana Tanase, Alistair J. Barber
Publikováno v:
Diabetes. 47:815-820
The early pathophysiology of diabetic retinopathy and the involvement of neural and vascular malfunction are poorly understood. Glial cells provide structural and metabolic support for retinal neurons and blood vessels, and the cells become reactive
Autor:
Christopher M. Domes, John M. Strother, Chantelle M. Rein, David H. Farrell, Thomas G. DeLoughery, Morgan M. Ballard, Kathryn K. M. Wolper, Andrew S. Terker, Brian L. Anderson, Russell J. Madsen, Joshua M. Johnston
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 21(5)
The dysfibrinogen gammaR275C can be a clinically silent mutation, with only two out of 17 cases in the literature reporting a hemorrhagic presentation and four cases reporting a thrombotic presentation. We describe here a particularly severe presenta
Autor:
John M. Strother, Charles D. Blanke
Publikováno v:
Current Clinical Oncology ISBN: 9781588297518
Angiogenesis is an essential step in the growth and metastases of many solid tumors,including colorectal cancer (CRC). Efforts to inhibit angiogenesis as a potential antineoplastic strategy began more than 30 yr ago, and numerous angiogenic growth fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f112491ac4c357a5043e933e647ec026
https://doi.org/10.1007/978-1-59745-215-1_5
https://doi.org/10.1007/978-1-59745-215-1_5
Publikováno v:
Endoscopic Oncology ISBN: 9781588295323
In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e649b2771505b97669c5324565120f45
https://doi.org/10.1007/978-1-59745-172-7_23
https://doi.org/10.1007/978-1-59745-172-7_23
Publikováno v:
European journal of cancer (Oxford, England : 1990). 41(6)
In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested
Autor:
Gina M. Vaccaro, John M. Strother, Kerstin M Kampa-Schittenhelm, Charles D. Lopez, Jeff Masterson, Andrea Burt
Publikováno v:
Journal of Clinical Oncology. 30:507-507
507 Background: Despite 1st-line response rates (RR) in mCRC of > 50% with FOLFOX or FOLFIRI, 2nd-line RRs are less (FOLFOX ~ 15%; FOLFIRI ~ 4%). Thus, there is a critical need for better 2nd-line strategies. Although use of anti-EGFR antibodies with